Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study

BACKGROUNDS: GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). This study aimed to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xiaonan, Song, Yuqin, Shi, Yuankai, Zhang, Qingyuan, Guo, Wei, Wu, Gang, Li, Junmin, Feng, Jifeng, Kinkolykh, Anastasiia, Knapp, Andrea, Lin, Tongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869628/
https://www.ncbi.nlm.nih.gov/pubmed/35194005
http://dx.doi.org/10.1097/CM9.0000000000001737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869628/
https://www.ncbi.nlm.nih.gov/pubmed/35194005
http://dx.doi.org/10.1097/CM9.0000000000001737

Ejemplares similares